LMR Partners LLP Invests $1.43 Million in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

LMR Partners LLP acquired a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the 4th quarter, Holdings Channel reports. The fund acquired 64,817 shares of the company’s stock, valued at approximately $1,429,000.

Several other institutional investors have also modified their holdings of TEVA. FMR LLC raised its position in Teva Pharmaceutical Industries by 30.7% in the 4th quarter. FMR LLC now owns 81,983,231 shares of the company’s stock valued at $1,806,910,000 after purchasing an additional 19,242,468 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd raised its position in Teva Pharmaceutical Industries by 12.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock valued at $859,935,000 after purchasing an additional 4,418,961 shares during the last quarter. Ion Asset Management Ltd. increased its stake in Teva Pharmaceutical Industries by 1.1% in the 4th quarter. Ion Asset Management Ltd. now owns 36,650,000 shares of the company’s stock valued at $807,766,000 after buying an additional 409,778 shares during the period. Lingotto Investment Management LLP increased its stake in Teva Pharmaceutical Industries by 2.6% in the 4th quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company’s stock valued at $599,320,000 after buying an additional 688,862 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. increased its stake in Teva Pharmaceutical Industries by 2.2% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company’s stock valued at $573,822,000 after buying an additional 569,412 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $17.48 on Wednesday. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The stock has a market cap of $19.82 billion, a PE ratio of -12.06, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The firm’s fifty day simple moving average is $15.22 and its 200-day simple moving average is $17.44.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The business had revenue of $3.89 billion for the quarter, compared to analysts’ expectations of $3.99 billion. During the same period in the prior year, the company posted $0.48 EPS. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. Analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have issued reports on TEVA shares. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research note on Monday, April 28th. Bank of America boosted their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. Barclays dropped their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Wednesday, April 23rd. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $24.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.